ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'"
Episode Synopsis
Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.
More episodes of the podcast The Weight Loss Podcast
GLP1 Improving Heart Health
21/11/2024
GLP1s - a deeper dive into how they work
01/11/2024
featured sponsor episode: tune-health
23/10/2024
In God we trust